Streetbeat News

ADC

Agree Realty Corporation

https://www.agreerealty.com

Industry

REIT - Retail

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Open

75.51

Mkt cap

8.2B

Volume

1.5M

High

76.94

P/E Ratio

43.19

52-wk high

78.39

Low

75.36

Div yield

0.04

52-wk low

54.78

ADC Therapeutics has released initial positive results from a phase 1b study using ZYNLONTA + COLUMVI for treating 2nd-line relapsed/refractory DLBCL. Further results are expected in the first half of 2025. The DLBCL market is projected to reach $5.25 billion by 2034.

Portfolio Pulse from

December 12, 2024 | 7:30 pm

ADC Therapeutics announced positive initial data from its LOTIS-7 clinical trial, showing that ZYNLONTA in combination with glofitamab is effective in treating relapsed/refractory diffuse large B-cell lymphoma, with a 94% overall response rate and 72% complete response rate. The treatment showed no dose-limiting toxicities or severe side effects.

Portfolio Pulse from

December 11, 2024 | 12:45 pm

The article discusses three durable dividend stocks that are recommended for long-term passive income due to their financial strength and resilient business models.

Portfolio Pulse from

December 08, 2024 | 12:00 pm

The article discusses the author's biggest regret as a REIT investor, despite outperforming sector averages over the long run. The focus is on a specific mistake that could have led to even better performance.

Portfolio Pulse from

December 07, 2024 | 1:45 pm

The U.S. stock market is experiencing high valuations driven by Big Tech and AI investments, similar to the late 1990s. While some REITs like W.P. Carey face challenges, others are undervalued due to short-term supply issues.

Portfolio Pulse from

December 07, 2024 | 1:30 pm

ADC Therapeutics SA will host a webcast on December 11, 2024, to provide an update on the LOTIS-7 clinical trial. The trial evaluates the safety and efficacy of ZYNLONTA® in combination with glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma.

Portfolio Pulse from

December 06, 2024 | 12:45 pm

Merck's sacituzumab tirumotecan, an ADC drug, has received the FDA's Breakthrough Therapy designation for treating non-small cell lung cancer (NSCLC). This is the first such designation for this drug in the United States.

Portfolio Pulse from

December 04, 2024 | 7:00 pm

Gilead Sciences has entered into a collaboration with German biotech company Tubulis to develop an antibody-drug conjugate (ADC) targeting solid tumors. This partnership aims to leverage Tubulis' expertise in ADC technology to enhance Gilead's oncology pipeline.

Portfolio Pulse from

December 04, 2024 | 4:30 pm

The article discusses five high-yielding quality stocks that offer solid passive income streams for dividend investors. These stocks are recommended for their potential to provide consistent monthly income.

Portfolio Pulse from

December 03, 2024 | 12:00 pm

ADC Therapeutics has granted options to purchase 34,900 common shares to three new employees as an inducement for their employment.

Portfolio Pulse from

December 02, 2024 | 9:45 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.